Dimethylformamide → Rifampicin

HRID 46715

Reaktionsgleichung

Reaktionsgleichung von HRID 46715
[CH3:1][C:2]1[C:7]2[O:8][C@:9]3([CH3:49])[O:12][CH:13]=[CH:14][C@H:15]([O:47][CH3:48])[C@@H:16]([CH3:46])[C@@H:17]([O:42][C:43]([CH3:45])=[O:44])[C@H:18]([CH3:41])[C@H:19]([OH:40])[C@H:20]([CH3:39])[C@@H:21]([OH:38])[C@@H:22]([CH3:37])[CH:23]=[CH:24][CH:25]=[C:26]([CH3:36])[C:27]([NH:29][C:30]4[C:34](=[O:35])[C:4](=[C:5]([C:32](=[O:33])[CH:31]=4)[C:6]=2[C:10]3=[O:11])[C:3]=1[OH:50])=[O:28].[CH3:51]N(C)C=O.C(N1CN(C(C)(C)C)CN(C(C)(C)C)C1)(C)(C)C.[NH2:74][N:75]1[CH2:80][CH2:79][N:78]([CH3:81])[CH2:77][CH2:76]1>C(O)(=O)C>[CH3:1][C:2]1[C:7]2[O:8][C@:9]3([CH3:49])[O:12][CH:13]=[CH:14][C@H:15]([O:47][CH3:48])[C@@H:16]([CH3:46])[C@@H:17]([O:42][C:43]([CH3:45])=[O:44])[C@H:18]([CH3:41])[C@H:19]([OH:40])[C@H:20]([CH3:39])[C@@H:21]([OH:38])[C@@H:22]([CH3:37])[CH:23]=[CH:24][CH:25]=[C:26]([CH3:36])[C:27]([NH:29][C:30]4[C:31](/[CH:51]=[N:74]/[N:75]5[CH2:80][CH2:79][N:78]([CH3:81])[CH2:77][CH2:76]5)=[C:32]([OH:33])[C:5]([C:6]=2[C:10]3=[O:11])=[C:4]([C:34]=4[OH:35])[C:3]=1[OH:50])=[O:28]

Komponenten

6

Edukt 4

HCID 6228DimethylformamideHCID 663521,3,5-Tris(1,1-dimethylethyl)hexahydro-1,3,5-triazineHCID 813491-Amino-4-methylpiperazineHCID 6436726Rifamycin S

Produkt 1

HCID 135398735Rifampicin

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 176Acetic AcidLösungsmittel

Versuchsvorschrift

15 g. Rifamycin S are dissolved in 50 ml. dimethylformamide and 5.5 g. 1,3,5-tri-(tert.-butyl)-hexahydro-1,3,5-triazine are added to the solution. The reaction mixture is then kept at 75° C. for about 3 hours and 1-amino-4-methylpiperazine, acidified with acetic acid, added directly according to the procedure described in Example 1, followed by analogous working up to give substantially pure rifampicin.

Aufarbeitung

  1. additionadded directly

Quellen und Nachweise

ORD-Eintrag
ord-1bae79cdb4cd473f92543be6b20fce4c
Quelldatensatz
uspto-grants-1979_11
Patentnummer
US04174320

Verknüpfte Notizen

Wird geladen…